This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Prescribing Information for NGENLA▼(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.


The recommended dose is 0.66 mg/kg bodyweight administered once weekly by subcutaneous injection. 

24mg Pen ​​​​​​​(20mg/ml)

60mg Pen (50mg/ml)

Suggested for doses less than 12mg
(bodyweight < 18kg)

​​​​​​​​​​​​​​Dose increments of 0.2mg

Suggested for doses 12mg and above
​​​​​​​ (bodyweight 18kg and over)

Doses > 30mg (ie. bodyweight > 45kg),
​​​​​​​two injections are needed.

​​​​​​​Dose increments of 0.5mg

Each prefilled pen is capable of setting and delivering the dose prescribed by the physician. Dose may be rounded up or down based on the physician's expert knowledge of the individual patient needs.

How to titrate the dose of NGENLA

Based on growth velocity, adverse reactions, body weight and serum insulin-like growth factor 1(IGF-1) concentrations. Note: When monitoring IGF-1, samples should always be drawn 4 days after prior dose. 

For full dosing details, refer to the Summary of Product Characteristics for NGENLA.

​​​​​​​Storage information​​​​​​​1​​​​​​​

Before first use

After first use

Prior to the first use, NGENLA may be stored for 3 years at 2–8°C in a refrigerator.
The unopened pre-filled pen may temporarily be held for up to 4 hours at temperatures up to 32 °C.

After first use, NGENLA may be stored for 28 days in a refrigerator (2 °C – 8 °C).

NGENLA may be held at room temperature (up to 32°C) for up to 4 hours with each injection for a maximum of 5 times. Return NGENLA to the refrigerator again after each use.
It should not be frozen and should be stored with the pen cap attached in order to protect from light. 

Refer to the Summary of Product Characteristics for NGENLA for full storage information.

The UnoPenTM device

NGENLA is administered by the pre-filled, multi-dose, disposable UnoPen – giving patients and caregivers the confidence to administer treatment and get back to moments that matter.

  • Low injection volume for paediatric patients (<0.6mL) and small needle gauge [31G-32G].
  • No reconstitution required.
  • Multidose, disposable and prefilled.
​​​​​​​The 24mg Pen is suggested for doses up to 12mg. The 60mg pen is suggested for doses 12mg and over.


NGENLA is to be injected in the abdomen, thighs, buttocks or upper arms. The site of injection should be rotated at each administration. Injections to the upper arms and buttocks should be given by the caregiver.

• Administer NGENLA once weekly, on the same day each week, at any time of the day.

• The day of weekly administration can be changed if necessary as long as the time between 2 doses is at least 3 days (>72 hours). 

• If a dose is missed, NGENLA should be administered as soon as possible within 3 days of the missed dose; then the usual once-weekly dosing schedule should be resumed. After 3 days of missed dose, the dose should be skipped and the next dose administered on the regular scheduled day.

Needle support

Sterile needles are required for administration but are not included in the NGENLA pack.

NGENLA can be administered with a needle from 4mm to 8mm and 31G or 32G.

Pfizer will provide a box of needles as standard within the patient starter box:
            - BD Micro-Fine Ultra 4mm 32G needles (quantity 100)

For resupply, or to order additional or different needles at no cost, the patient/caregiver or Healthcare Professional can contact the Endocrine Helpline on 0800 521249 or [email protected]

NGENLA Instructions for Use Video

View the video for guidance on how NGENLA is prepared and administered.

Explore more

Access PIP Codes and key details on how to order NGENLA for your patients.

Ordering Information

Access practical support for initiating patients on NGENLA and learn more about how NGENLA may deliver a treatment experience favoured by patients and caregivers.​​​​​​​2

Initiating NGENLA

​​​​​​​1. ​​NGENLA Summary of Product Characteristics for Great Britain: & Northern Ireland:
2. Maniatis AK, Carakushansky M, Galcheva S, et al. Perception of treatment burden with once weekly Somatrogon vs once daily Genotropin in pediatric patients with growth hormone deficiency: results from a randomized phase 3 study. Poster 6895 presented at: Annual Meeting of the Endocrine Society [virtual]; March 20-23, 2021.
PP-NGE-GBR-0036. May 2022.

Find out information about the starter kits available to patients starting treatment with NGENLA.

Starter kits

Download the document to access information supporting fomulary application for NGENLA.

Formulary pack

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?